durvalumab,cisplatin,gemcitabine
astrazeneca
[]
1st conference of 2023! #gi23 highlights include
-lots of interest for my poster on cost of cholangio trx with durva
-gaining inspiration for targetable mutations in pancreas
-learning when a negative trial can be helpful thankful for mentors 
Rice ‘18 | @NIH MRSP Scholar ‘22-23 | UTMB ‘24 | Pancreatic Genomics | GI Health Disparities | Alewine Lab | Texas ACP MSC Chair | 🇲🇽 🇲🇽 🇲🇽